Claim Missing Document
Check
Articles

Found 2 Documents
Search

Comparison of 25-Hydroxyvitamin D Levels in Acute Coronary Syndrome Rahmafindari, Mirna; Anniwati, Leonita; Aminuddin, Muh.; Marpaung, Ferdy R.
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol 26, No 3 (2020)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v26i3.1560

Abstract

Vitamin D deficiency is associated with cardiovascular disease, one of, which is an Acute Coronary Syndrome (ACS). Some studies provide varying results, the 25 (OH)D levels, which can cause acute coronary syndrome is still controversial. This was an observational analytical study with a cross-sectional design. Samples were collected during April-September 2019 from the Dr. Soetomo Hospital, Surabaya. Patients with the acute coronary syndrome (70 persons) consisted of ST-Elevation Myocardial Infarction (STEMI), non-ST-Elevation Myocardial Infarction (NSTEMI), Unstable Angina (UA) were measured for 25 (OH)D and the differences in levels of 25 (OH)D between groups. Examination of 25 (OH)D used a competitive antibody method chemiluminescence immunoassay. There were different levels of 25 (OH)D patients with ACS versus healthy persons, p=0.0001. There was no difference in levels of 25 (OH)D in UA patients versus healthy persons, p=0.925. Acute coronary syndrome patients had higher 25 (OH)D levels than healthy persons, so it seemed that vitamin D did not play an essential role in the occurrence of ACS based on this study. This study showed that there were significant differences between 25 (OH)D levels in STEMI and healthy persons, NSTEMI and healthy persons, STEMI and NSTEMI, STEMI and UA, NSTEMI and UA. In the UA group and healthy persons, no statistically significant differences were found.
High Sensitive Troponin I and Extended Range C-Reactive Protein as Markers to Predict Cardiotoxicity in Locally Advanced Breast Cancer with Neoadjuvant CAF (Cyclophoshpamide, Adriamycin/Doxorubicin, 5Fluorouracil) Therapy Hidayat, Yusfik Helmi; Ishardyanto, Hantoro; Anniwati, Leonita
Folia Medica Indonesiana Vol. 56, No. 2
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The limitation of echocardiography to measure chemotherapy cardiotoxicity at left locally advanced breast cancer with large ulcer is still serious problem. HsTnI and erCRP are biomarkers to detect cardiotoxicity that are cheap, easy to examine and available at Dr.Soetomo Hospital Surabaya. This study was to compare HsTnI, erCRP and echocardiography as cardiotoxicity predictors in locally advanced breast cancer with neoadjuvant CAF therapy. This study used one group pretest and posttest design among 23 locally advanced breast cancer patients. All patients underwent echocardiography, HsTnI, and erCRP examinations before and after 3 times chemotherapy and compared. The average age was 49.78±8.7. Statistically significant decrease in LVEF was found after treatment (67.98%±4.06 and 64.07%±3.53, p=0.000). HsTnI was significantly increased after treatment (0.007 µg/mL±0.004 and 0.043 µg/mL±0.051 p=0.000). erCRP was significantly decreased after treatment (1.043mg/dL±0.913 and 0.573mg/dL±0.444 p=0.044). Decreased LVEF and increased HsTnI was compared by its cardiotoxic cut-off. HsTnI was significantly better and faster to detect cardiotoxicity (0.033±0.051 p=0.002). In conclusion, strong correlation is present in the detection of cardiotoxicity between HsTnI and LVEF. HsTnI is faster than echocardiography, and could be alternative diagnostic to detect early cardiotoxicity.